A
Andreessen Horowitz LLC
+ HoldingBRVE
+10.79%
3M Return
$27.440
-0.414 (-1.51%)Al cierre
Loading chart…
- High
- 29.240
- Open
- 27.980
- VWAP
- 28.02
- Vol
- 162.46K
- Mkt Cap
- —
- Low
- 27.380
- Amount
- 4.55M
- EV/EBITDA, TTM
- 0.00
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.
AI analysis of Braveheart Bio, Inc. (BRVE)
buyBraveheart Bio, Inc. is a good buy right now, especially considering the recent insider purchases and strong IPO performance. The stock closed at $27.44, which is significantly higher than the IPO price of $18, reflecting a $12 gain per share. Furthermore, the company's forward P/E is 0, indicating potential for future earnings growth as it progresses in its clinical trials.
Métricas de valoración
The current forward P/E ratio for Braveheart Bio, Inc. (BRVE) is 0.00, compared to its 5-year average forward P/E of .
Whales holding BRVE
Cronología de eventos
Noticias
2.008-31CNBCKey Wall Street Rating Updates on Monday
8.508-10FoolDirector Viehbacher Increases Stake in Braveheart Bio
8.508-10FoolBraveheart Bio CFO Acquires Significant Shares Amid Positive Market Signals
8.508-10NASDAQ.COMBraveheart Bio Director Increases Shareholding
8.508-10FoolBraveheart Bio CEO Increases Shareholding
BRVE FAQ — answered by Alphio AI
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart. It operates in the Healthcare sector.
Braveheart Bio, Inc. is a good buy right now, especially considering the recent insider purchases and strong IPO performance. The stock closed at $27.44, which is significantly higher than the IPO price of $18, reflecting a $12 gain per share. Furthermore, the company's forward P/E is 0, indicating potential for future earnings growth as it progresses in its clinical trials.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.